RLMD — Relmada Therapeutics, Inc.

Summary of Relmada Therapeutics Q1 2026 Earnings Call

1. Key Financial Results and Metrics

• Cash Position: Relmada closed Q1 2026 with a cash balance of $234 million, significantly up from $94 million at the end of 2025, bolstered by $150 million from a private financing.
• Net Loss: The company reported a net loss of $19.1 million (or $0.22 per share) for Q1 2026, compared to a net loss of $17.6 million (or $0.58 per share) in Q1 2025.
• R&D Expenses: R&D expenses decreased to $8.1 million from $12 million in the prior year, attributed to nonrecurring costs from previous acquisitions.
• G&A Expenses: General and administrative expenses rose to $11.4 million, up from $6.3 million in the same period last year, mainly due to increased compensation costs.

2. Strategic Updates and Business Highlights

• NDV-01 Development: Positive 12-month efficacy data from the ongoing Phase 2 study of NDV-01 for non-muscle invasive bladder cancer (NMIBC) was highlighted, showing a 95% complete response rate at any time and a 76% durable response rate at 12 months.
• Phase 3 Program: The company is on track to initiate a Phase 3 rescue program for NDV-01 in mid-2026, with FDA alignment achieved for the registration pathway.
• Patent Filing: A provisional patent application for NDV-01 was filed, potentially extending patent protection until 2047, which could enhance the company’s competitive position.
• Cipranolone Study: Plans to initiate a proof-of-concept study for Cipranolone in Prader-Willi syndrome are set for mid-2026.

3. Forward Guidance and Outlook

• Relmada expects its current cash resources to fund operations through 2029, including the completion of the Phase 3 rescue program for NDV-01.
• The company anticipates presenting compelling data at the upcoming American Urological Association (AUA) meeting, which could bolster interest and support for NDV-01.

4. Bad News, Challenges, or Points of Concern

• Increased G&A Expenses: The significant rise in general and administrative expenses may raise concerns about cost management as the company scales operations.
• Market Competition: The competitive landscape for bladder cancer treatments remains challenging, with existing therapies showing varying efficacy rates, which could impact NDV-01's market entry.
• Regulatory Risks: The success of the Phase 3 program and subsequent regulatory approvals are contingent on meeting FDA expectations, particularly regarding efficacy and safety data.

5. Notable Q&A Insights

• Efficacy Benchmarks: Management indicated that achieving an 80-85% complete response rate in the BCG-unresponsive population would be considered best-in-class, significantly higher than existing therapies.
• Enrollment Expectations: The company is optimistic about enrollment timelines for the Phase 3 studies, anticipating a 12-month enrollment period for the second-line therapy.
• Patent Clarification: Management clarified that the new patent could provide extended coverage, allowing for potential future clinical trials and studies beyond the current rescue program, enhancing strategic flexibility.

Overall, Relmada Therapeutics is positioned with a strong cash position and promising clinical data, but faces challenges related to rising operational costs and competitive pressures in the oncology market.